AerWave Medical has concluded the feasibility study of its ultrasound lung denervation therapy, designed to treat chronic obstructive pulmonary disease (COPD) and asthma.
The first-in-human study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave’s disease-modifying technology, which aims to simplify lung denervation by removing the need for fluoroscopic guidance and other conventional requirements.
Go deeper with GlobalData
The ultrasound platform claims to deliver circumferential ablation in a single energy application.
This method is intended to minimise airway smooth muscle constriction, tackling the root causes of COPD and asthma rather than just managing the symptoms.
Aerwave Medical chief technology officer Reinhard Warnking said: “Our approach represents a paradigm shift in interventional pulmonology.
“By harnessing the advantages of ultrasound energy over heat conducting approaches, we address longstanding challenges in treating airway diseases. Our technology enables targeted interventions that minimise the potential for collateral damage while enhancing procedural efficiency and efficacy.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“These advancements hold immense promise not only for asthma and COPD but also for emerging applications like lung tumour ablation and lung volume reduction, demonstrating the potential to redefine standards of care in pulmonary medicine.”
AerWave’s ultrasound platform provides treatment through a single targeted ablation procedure, reduces procedure time using a single-shot approach and does not require fluoroscopy or additional devices.
The scope of AerWave’s platform also includes conformal lung tumour ablation (LTA) and lung volume reduction (LVR).
Conformal LTA can spare healthy tissue while targeting larger lesions through pulsed operation. Meanwhile, LVR offers a non-surgical alternative for reducing emphysematous tissue volume through localised fibrotic reactions.
By using the capabilities of ultrasound to deliver energy and avoid harming surrounding tissues, these applications could provide new treatment avenues.
